This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (30)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • HIV/AIDS  • Drug Therapy  • Drug Therapy, Other  • Infectious Diseases  • Alert me on articles by topic  Social Bookmarking   What's this?

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: Anecdotal reports have suggested that individuals with preexisting human immunodeficiency virus (HIV) infection may be at risk for superinfection by different strains of HIV.^1-3 We investigated the incidence of superinfection 6 to 12 months after a first diagnosis of HIV infection.

Methods

We included all recently infected antiretroviral-naive participants (n = 78) in the San Diego and Los Angeles Acute Infection and Early Disease Research Programs between December 1997 and June 2003 who had deferred antiretroviral treatment for at least the first 6 months after diagnosis. We retrospectively analyzed blood samples collected at the time of enrollment and then another sample 6 to 12 months later. Superinfection screening was performed on both sets of samples by population-based sequencing of pol from plasma HIV RNA using Viroseq version 2.0 (Celera Diagnostics, Foster City, Calif).

Superinfection was suspected when isolates from the same individual shared their most recent common ancestor . . . [Full Text of this Article]

Davey M. Smith, MD
d13smith@ucsd.edu
Department of Medicine
University of California, San Diego
La Jolla

Joseph K. Wong, MD; George K. Hightower, BA; Caroline C. Ignacio, BS; Kersten K. Koelsch, MD
Department of Medicine
University of California, San Diego

Eric S. Daar, MD
Division of HIV Medicine, Harbor-UCLA Research and Education Institute and the David Geffen School of Medicine at UCLA
Los Angeles, Calif

Douglas D. Richman, MD
Departments of Medicine and Pathology
University of California, San Diego
San Diego Veterans Affairs Healthcare Systems

Susan J. Little, MD
Department of Medicine
University of California, San Diego

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Partial Protection of Simian Immunodeficiency Virus (SIV)-Infected Rhesus Monkeys against Superinfection with a Heterologous SIV Isolate
Yeh et al.
J. Virol. 2009;83:2686-2696.
ABSTRACT | FULL TEXT  

Human Immunodeficiency Virus Type 1 Superinfection Occurs despite Relatively Robust Neutralizing Antibody Responses
Blish et al.
J. Virol. 2008;82:12094-12103.
ABSTRACT | FULL TEXT  

Persistence of Transmitted Drug Resistance among Subjects with Primary Human Immunodeficiency Virus Infection
Little et al.
J. Virol. 2008;82:5510-5518.
ABSTRACT | FULL TEXT  

Mapping Protease Inhibitor Resistance to Human Immunodeficiency Virus Type 1 Sequence Polymorphisms within Patients
Poon et al.
J. Virol. 2007;81:13598-13607.
ABSTRACT | FULL TEXT  

Prevalence and determinants of transmitted antiretroviral drug resistance in HIV-1 infection
Booth and Geretti
J Antimicrob Chemother 2007;59:1047-1056.
ABSTRACT | FULL TEXT  

Extensive Intrasubtype Recombination in South African Human Immunodeficiency Virus Type 1 Subtype C Infections
Rousseau et al.
J. Virol. 2007;81:4492-4500.
ABSTRACT | FULL TEXT  

Neutralizing Antibody Responses against Autologous and Heterologous Viruses in Acute versus Chronic Human Immunodeficiency Virus (HIV) Infection: Evidence for a Constraint on the Ability of HIV To Completely Evade Neutralizing Antibody Responses.
Deeks et al.
J. Virol. 2006;80:6155-6164.
ABSTRACT | FULL TEXT  

Evidence for Frequent Reinfection with Human Immunodeficiency Virus Type 1 of a Different Subtype
Chohan et al.
J. Virol. 2005;79:10701-10708.
ABSTRACT | FULL TEXT